Canopy Growth (TSX:WEED) Earnings Drag Cannabis Stocks Lower

Canopy Growth spooked investors after fiscal second quarter of 2020 sales and earnings are well below consensus estimates.

| More on:
Volatile market, stock volatility

Image source: Getty Images

Shares of Canada’s leading cannabis company Canopy Growth (TSX:WEED)(NYSE:CGC) fell 14.5% yesterday after it announced fiscal second quarter of 2020 (year ending in March) results.

In the September quarter, Canopy Growth reported sales of $76.6 million, a year-over-year growth of 228% compared to sales of $23.33 million in the prior-year period. The company’s earnings per share improved from -$1.52 to -$1.08 in the same period.

Canopy reported earnings and revenue significantly below consensus estimates. Analysts estimated Canopy Growth to post sales of $108.48 million and EPS of -$0.39 in the fiscal second quarter. Net revenue also fell 15% compared to sales of $90.5 million in the first quarter of fiscal 2020.

The company’s less-than-impressive results dragged the entire cannabis sector lower. Shares of Aurora Cannabis, Hexo, and Cronos were down by 8.7%, 7.6%, and 4.2%, respectively, on November 14, 2019. Horizons Marijuana Life Sciences ETF was also down 5.3% yesterday.

What drove Canopy Growth sales in Q2?

In the September quarter, Canopy Growth established a market share of 35% in Alberta, which is considered to be the country’s most developed provincial recreational market. The company continued to benefit from the growing demand for cannabis.

Its same-store sales in recreational cannabis rose 17%, while global medical organic growth was 23% on a sequential basis. However, the lower-than-expected sales were attributed to a challenging market environment.

Several provinces have reduced demand to lower inventory levels. Further, as cannabis is a highly regulated market, the retail store openings have not been on expected levels. Though several companies have invested heavily in cannabis-infused vapes, edibles, and concentrates, these products will not hit retail shelves till mid-December.

Canopy Growth CEO Mark Zekulin stated, “The last two quarters have been challenging for the Canadian cannabis sector as provinces have reduced purchases to lower inventory levels, retail store openings have fallen short of expectations, and Cannabis 2.0 products are yet to come to market … However, we believe these conditions are a short-term headwind in what is a brand-new industry, and Canopy continues to be best positioned with cash-on-hand, a world-class infrastructure, and a portfolio of intellectual property to deliver sustained, long-term market leadership.”

What’s next for Canopy Growth and investors?

Shares of Canopy Growth are currently trading at $20.7, which is 72% below its 52-week high of $71. Investors have lost significant wealth in the last year after the euphoria about the legalization of recreational cannabis had run its course.

So, how is Canopy Growth looking to solve lower demand and rising inventory levels? At the end of the September quarter, Canopy had inventory worth $461.8 million, which is massive given the tepid demand.

The company’s management has initiated a portfolio review, which resulted in restructuring charges of $32.7 million for returns, returns provisions, and pricing allowances. This strategy includes a new retail pricing architecture, a rationalized package assortment and a focus on a marketing strategy to increase consumer awareness.

Canopy Growth has submitted over 30 SKUs (stock-keeping units) to Health Canada for approval of Cannabis 2.0 products, including chocolates, vapes, and beverage formats. The cannabis-infused edibles will be a critical driver of sales. But as we know, it is too early to estimate demand in a market that is facing teething and regulatory issues.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO. and HEXO. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

Why Canopy Growth Stock Jumped 16% on Wednesday

Canopy Growth stock (TSX:WEED) is up 16% on Wednesday, adding to a surge of 60% growth in the last week…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »